AI450540 Inhibitors
Chemical inhibitors of AI450540 can be understood through various biochemical and cellular mechanisms by which they influence the activity of this protein. Staurosporine, a broad-spectrum kinase inhibitor, can inhibit AI450540 by obstructing the kinases responsible for its phosphorylation, a post-translational modification essential for the protein's function. Similarly, Dasatinib, which targets tyrosine kinases, can inhibit AI450540 by suppressing the action of kinases that may activate AI450540. The proteasome inhibitor Bortezomib can lead to the inhibition of AI450540 by causing an accumulation of ubiquitinated proteins, implying a potential block in the degradation pathway that regulates the protein's turnover and, consequently, its function.
Further, the macrolide compound Rapamycin can inhibit AI450540 by binding to mTOR, thus inhibiting a pathway that could be essential for AI450540's activity. LY294002 and Wortmannin, both PI3K inhibitors, can inhibit AI450540 by blocking the AKT pathway, which may be necessary for the activation or function of AI450540. U0126 and PD98059, as MEK inhibitors, prevent the activation of ERK; if AI450540 is reliant on the ERK pathway, these inhibitors would consequently prevent its activation. Additionally, SB203580's inhibition of p38 MAP kinase can suppress AI450540 by disrupting the signaling necessary for its activation or stabilization.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine, a potent kinase inhibitor, can inhibit AI450540 by targeting the kinases that phosphorylate AI450540, thus inhibiting its activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits the proteasome, which can lead to the accumulation of ubiquitinated proteins, potentially inhibiting AI450540 by preventing its degradation-based regulation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib selectively inhibits tyrosine kinases that could be upstream regulators or direct activators of AI450540, thus inhibiting its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to mTOR, which can inhibit the mTOR signaling pathway that may be crucial for the activity of AI450540, thus inhibiting AI450540. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which is involved in the AKT signaling pathway; by inhibiting this pathway, AI450540, which may rely on PI3K signaling, is consequently inhibited. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor, which prevents the activation of ERK; inhibiting this pathway can lead to the functional inhibition of AI450540 if it is ERK-dependent. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAP kinase; inhibition of p38 MAPK can inhibit AI450540 activity by blocking the pathway necessary for its activation or stability. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, thereby inhibiting AI450540 if the activity of AI450540 is regulated through JNK signaling pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that prevents ERK activation; by inhibiting ERK signaling, AI450540, which may be dependent on this pathway, is inhibited. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor, which can inhibit AI450540 by blocking the AKT pathway necessary for its activation or function. | ||||||